A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of IgPro20
(subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). The primary
objective of this study is to assess the efficacy of IgPro20 subcutaneous (SC) doses in
comparison to placebo in adult subjects with DM, as measured by responder status based on
Total Improvement Score (TIS) assessments.
Phase:
Phase 3
Details
Lead Sponsor:
CSL Behring
Treatments:
Antibodies Immunoglobulin G Immunoglobulins Immunoglobulins, Intravenous